Doctors Note Logo

Published on: 8/18/2026

Why Adult Fractures Occur Without Trauma: HPP Reality & Steps

Adult fractures that happen with little or no injury, often in the feet, thighs, or ribs, can signal an underlying bone metabolism problem rather than simple bad luck, and hypophosphatasia (HPP) is one under-recognized genetic cause tied to low alkaline phosphatase activity, poor mineralization, early tooth loss, chronic bone pain, and stress fractures that heal slowly. Other contributors include osteoporosis, vitamin D or calcium deficiency, long-term steroid or bisphosphonate use, thyroid and parathyroid disorders, and repetitive overuse, so there are several important factors to consider before assuming any single diagnosis. Key steps include reviewing your full fracture history, checking alkaline phosphatase and vitamin D levels, bone density imaging, and asking about genetic testing when results and symptoms point toward HPP, all of which are explained in more detail below. Because low-trauma fractures often repeat and worsen without the right workup, tracking your symptoms early gives your clinician the pattern they need to act quickly. Start with a free, instant, online symptom check to organize what you are experiencing and better understand which next steps and specialists may fit your situation.

Last reviewed for medical accuracy: 08/18/2026

answer background

Explanation

Why Adult Fractures Occur Without Trauma: HPP Reality & Steps

Unexplained fractures in adults—sometimes after minimal or no apparent injury—can be alarming. One under‐recognized cause is hypophosphatasia (HPP), a genetic disorder that impairs bone mineralization. Recognizing hypophosphatasia adults symptoms can lead to earlier diagnosis, clearer management and better outcomes.

What Is Hypophosphatasia?

Hypophosphatasia is a rare inherited condition caused by mutations in the ALPL gene, which encodes tissue-nonspecific alkaline phosphatase. Low enzyme activity leads to:

  • Poor bone and tooth mineralization
  • Build-up of substrates like inorganic pyrophosphate
  • A spectrum of severity from life-threatening infantile forms to mild adult‐onset disease

Adults with HPP often go years without a correct diagnosis, believing their aches or stress fractures are simply “wear and tear.”

How HPP Leads to Fractures Without Trauma

In healthy bone, alkaline phosphatase helps lay down hydroxyapatite (the mineral backbone). In HPP:

  1. Alkaline phosphatase levels remain low.
  2. Mineralization of bone matrix is incomplete.
  3. Bone becomes porous, brittle and prone to stress fractures or breaks during everyday activities.

Even routine activities—walking, mild exercise, turning in bed—can cause a crack or frank fracture in weakened bone.

Key hypophosphatasia adults symptoms

Symptoms vary widely, but common features in adult‐onset HPP include:

  • Recurrent stress fractures (often in feet, legs or ribs)
  • Non-healing fractures or delayed healing
  • Chronic musculoskeletal pain, stiffness or weakness
  • Early loss of adult teeth (especially lower incisors)
  • Joint pain or chondrocalcinosis (calcium deposits in joint cartilage)
  • Low serum alkaline phosphatase on routine blood work
  • Episodes of muscle cramps or bone pain

Because many of these overlap with common conditions (arthritis, osteoporosis, repetitive strain), HPP can be overlooked.

Diagnosing Hypophosphatasia

Timely diagnosis relies on a combination of clinical suspicion and specific testing:

  1. Blood tests

    • Low alkaline phosphatase (ALP) activity—key red flag
    • Elevated substrates: pyridoxal-5′-phosphate (vitamin B6) and inorganic pyrophosphate
  2. Imaging studies

    • X-rays may show pseudofractures (Looser zones)
    • Bone density scans can be misleadingly normal or low
  3. Genetic testing

    • Confirms mutations in the ALPL gene
    • Helps predict disease severity and guide family counseling
  4. Specialist evaluation

    • Endocrinologist or metabolic bone specialist for interpretation of findings

Managing and Treating HPP

While there’s no simple “cure,” targeted and supportive therapies can significantly improve quality of life:

  • Enzyme replacement therapy
    Asfotase alfa (Strensiq®) replaces deficient alkaline phosphatase and is approved for pediatric and adult HPP in many regions.
  • Pain management
    Non-steroidal anti-inflammatory drugs (NSAIDs) and physical therapy for musculoskeletal pain.
  • Orthopedic care
    Surgical fixation for serious fractures—avoid prolonged immobilization when possible to reduce bone loss.
  • Vitamin supplementation
    Pyridoxine (vitamin B6) may help with certain neurologic symptoms; monitor calcium and vitamin D carefully.
  • Avoid certain medications
    Bisphosphonates, commonly used in osteoporosis, can worsen HPP by further inhibiting bone turnover; always discuss any new drug with your doctor.

Lifestyle and Supportive Strategies

Day-to-day adjustments can reduce fracture risk and ease symptoms:

  • Low-impact exercise
    Swimming, cycling or water aerobics strengthen muscles without jarring bones.
  • Balanced nutrition
    Adequate protein, calcium and vitamin D support bone metabolism—work with a dietitian if needed.
  • Fall prevention
    Home safety assessments, proper footwear and strength/balance training reduce accidental knocks.
  • Dental care
    Early and regular dental exams can address tooth loss or delayed eruption issues.
  • Emotional and social support
    Connect with HPP patient groups or counselors to manage chronic illness stress.

Next Steps & When to Seek Help

If you’ve experienced unexplained fractures, chronic bone pain or early tooth loss, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. It’s a quick way to gather your symptoms and discuss results with your healthcare provider.

Always speak to a doctor about anything that could be life-threatening or serious. Early recognition of HPP can change your treatment plan and help prevent further fractures. If HPP is confirmed, work closely with an endocrinologist or metabolic bone specialist for a personalized management approach.

(References)

  • * Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trence DL, Wilson DP, Lewiecki EM. Osteoporosis: Clinical Evaluation. 2000. PMID: 25905277.

  • * Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trence DL, Wilson DP, Marini JC, Dang Do AN. Osteogenesis Imperfecta. 2000. PMID: 25905334.

  • * Linglart A, Biosse-Duplan M. Hypophosphatasia. Curr Osteoporos Rep. 2016 Jun;14(3):95-105. doi: 10.1007/s11914-016-0309-0. PMID: 27084188.

  • * Kishnani PS, Rush ET, Arundel P, Bishop N, Dahir K, Fraser W, Harmatz P, Linglart A, Munns CF, Nunes ME, Saal HM, Seefried L, Ozono K. Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa. Mol Genet Metab. 2017 Sep;122(1-2):4-17. doi: 10.1016/j.ymgme.2017.07.010. Epub 2017 Jul 25. PMID: 28888853.

  • * Fenn JS, Lorde N, Ward JM, Borovickova I. Hypophosphatasia. J Clin Pathol. 2021 Oct;74(10):635-640. doi: 10.1136/jclinpath-2021-207426. Epub 2021 Apr 30. PMID: 33931563.

  • * Tournis S, Yavropoulou MP, Polyzos SA, Doulgeraki A. Hypophosphatasia. J Clin Med. 2021 Dec 1;10(23). doi: 10.3390/jcm10235676. Epub 2021 Dec 1. PMID: 34884378; PMCID: PMC8658462.

  • * Riancho JA. Diagnostic Approach to Patients with Low Serum Alkaline Phosphatase. Calcif Tissue Int. 2023 Mar;112(3):289-296. doi: 10.1007/s00223-022-01039-y. Epub 2022 Nov 8. PMID: 36348061.

  • * Schini M, Vilaca T, Gossiel F, Salam S, Eastell R. Bone Turnover Markers: Basic Biology to Clinical Applications. Endocr Rev. 2023 May 8;44(3):417-473. doi: 10.1210/endrev/bnac031. PMID: 36510335; PMCID: PMC10166271.

  • * Reis FS, Lazaretti-Castro M. Hypophosphatasia: from birth to adulthood. Arch Endocrinol Metab. 2023 May 25;67(5):e000626. doi: 10.20945/2359-3997000000626. PMID: 37249457; PMCID: PMC10665056.

  • * Magagnoli J, Knopf K, Hrushesky WJ, Carson KR, Bennett CL. Ferric Carboxymaltose (FCM)-Associated Hypophosphatemia (HPP): A Systematic Review. Am J Hematol. 2025 May;100(5):840-846. doi: 10.1002/ajh.27598. Epub 2025 Feb 11. PMID: 39935027; PMCID: PMC11966349.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.